A researcher affiliated with the University of Florida’s Sepsis and Critical Illness Research Center (SCIRC) has been awarded a U.S. patent for a novel therapeutic approach targeting key metabolic pathways involved in disease progression.
The patent, titled “Polypeptide Inhibitor of De Novo Lipogenesis in Cancer Cells,” was issued on September 17, 2024, and is assigned to the University of Florida Research Foundation.
Guimei Tian, MS, Biological Scientist II SCIRC, of the University of Florida, is listed among the inventors, contributing to this innovative work focused on disrupting pathways that regulate lipid metabolism. These pathways are increasingly recognized as critical drivers of pathological cellular activity, with potential implications for therapeutic development across a range of diseases.
This research aligns with SCIRC’s broader mission to advance translational science that improves patient outcomes following critical illness. By integrating mechanistic discovery with clinical insight, SCIRC investigators continue to develop precision-based strategies aimed at not only improving survival but also enhancing long-term recovery.
“This recognition highlights the importance of continuing to push the boundaries of discovery in complex disease states,” said Philip A. Efron, MD, Director of the Sepsis and Critical Illness Research Center (SCIRC). “Our work is focused on identifying actionable pathways that can be leveraged to improve patient care, and Guimei and her collaborators have done exactly that.”
“This type of work exemplifies the strength of team-based science,” said Robert Maile, PhD, Co-Director of SCIRC. “By bringing together expertise across disciplines, we are advancing our understanding of complex biological systems and driving meaningful progress in research.”
The issuance of this patent underscores SCIRC’s commitment to fostering innovation and supporting research that bridges the gap between the laboratory and the bedside.